publication date: May 10, 2012
|
author/source: Frost & Sullivan
A
monumental discovery that provides the promise of a cure not only for
leukaemia, but cancer at large was announced this morning in London during GIL
2012: Europe. Steve Shor, the founder of the National Children's Leukemia
Foundation, a leading non-profit organisation in the United States, unveiled a
ground-breaking therapy his research teams in the United States and Israel have
discovered. Mr Shor and National Program Director, Dr. Sara Gardin, presented
this new non-embryonic stem cell treatment for cancer and leukaemia, referred
to as the "Stem cell cocktail" which delivers a combination of
therapies including core stem cells and various compounds to tackle cell
metastasization.
Just
a few weeks ago, this unique approach to tackling one of the most prominent
forms of cancer of our time received initial patent approval with full patents
expected in the coming months.
Steve
Shor delivered an emotional appeal and address that captured the undivided
attention of some two hundred plus senior level business executives
representing this global network of visionaries, innovators and leaders
gathered in London for Frost & Sullivan's GIL 2012: Europe - Journey to
Visionary Innovation. Mr Shor, a construction business owner from Brooklyn, New
York, who had given up his successful career in 1992 to search out a bone
marrow donor, when he discovered that his 17-year old son had been diagnosed
with leukaemia. His son unfortunately never received a bone marrow transplant
and lost his fight with leukaemia. Steve has continued to dedicate his life to
cancer research founding the National Children's Leukemia Foundation and
working with scientists in hopes to find "The Cure."
"I
always thought the cure for cancer had to come from core stem cells,"
Steve said. "We started from a very different point. We asked: what are
the mechanisms that make cancer cells grow?"
First
time trial left them sceptical but upon continuous trials with positive
outcomes, the team at the NCLF research institute in Israel knew they have
uncovered a ground breaking monumental discovery with not only finding promise
in a cure and treatment for leukaemia, but all cancers as well.
"A cure not only for leukaemia but cancer at
large is within reach. We will see a cure for cancer within
our generation", concluded Mr Shor.
Steve Shor was recognised for his visionary leadership
in finding a cure for leukaemia by the Frost & Sullivan community of
visionaries, innovators and leaders - GIL Global with the presentation of Frost
& Sullivan's 2012 Growth, Innovation and Leadership Lifetime Achievement
Award by Vice President & Global Head of GIL, Brian Denker.
"One year ago, I stood here in London and posed a
question to our GIL Europe delegation -- What is a world without cancer? Today,
a year later, I return back to this side of the Atlantic with a promise of hope
by way of an individual who has successfully found visionary innovation in his
own journey in the wake of tragedy and struggle." Denker concluded by asking
each member of the GIL Global community to go forward, continually revisiting
three profound questions we all must continue to ask ourselves. Firstly, what
does it mean to truly innovate; second, what does it mean to inspire; and
lastly, how can we ourselves bridge innovation and inspiration?
To
know more about Frost & Sullivan's journey to visionary innovation,
please contact
Chiara Carella, Corporate Communications.
Subscribe to any of our newsletters for the latest on new laboratory products, industry news, case studies and much more!
Request your free copies HERE
Popular this Month
Top 10 most popular articles this month
Today's Picks
Looking for a Supplier?
Search by company or by product
Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.
Lab Bulletin is published by newleaf marketing communications ltd.